Refine by
Immune Cell Suppliers & Manufacturers
129 companies found
based inPhiladelphia, PENNSYLVANIA (USA)
With extensive experience optimising processes for analytical, production and R&D laboratories across multiple industries and regulatory environments, we provide consistent, quality informatics solutions. We operate on a truly global basis, serving ...
Create physiologically relevant cell culture models. Gibco Human Plasma-like Medium (HPLM) is a new formulation designed to resemble the natural cellular environment found in the body, mimicking the metabolic profile of human plasma. The widely used ...
based inWürzburg, GERMANY
Toleris Biotherapeutics GmbH is a biotechnology company based in Würzburg, Germany. The company specializes in the development of innovative biotherapeutic solutions aiming to advance the field of medicine through cutting-edge scientific research. ...
AIM Bio has developed a platform of Autoimmunity Modifying Biologicals (AIM Biologicals) that uses soluble, near-physiological proteins to induce selective, antigen-specific immune tolerance. These proteins mimic a natural process ...
based inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
based inTokyo, JAPAN
Healios will expand the possibilities for curing diseases to increase and further enrich quality of life through the development and supply of regenerative medicine products as part of the rapid progress of regenerative medicine taking place in the ...
Cancer is the leading cause of death in Japan, with approximately 90% of those deaths said to be caused by solid ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
based inTel-Aviv, ISRAEL
RedHill Biopharma (NASDAQ: RDHL) is driven to develop extraordinary medicines for people to live extraordinary lives. RedHill applies innovation, focus and a collective mindset of delivering on our promises, to build a company at the forefront of ...
Opaganib (ABC294640) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory and anti-viral ...
based inBasel, SWITZERLAND
Aurealis Therapeutics, a Swiss-Finnish private biopharmaceutical company, is now entering the clinical trial phase with its patented three-in-one combination product AUP-16 for chronic non-healing wounds and other regenerative diseases. The ...
Our new approach to chronic wound healing moves far beyond symptom ...
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; ...
based inNew York, NEW YORK (USA)
ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ...
based inSan Francisco, CALIFORNIA (USA)
Cypre is a biotechnology company dedicated to overcoming therapeutic resistance for cancer patients. Our 3D Tumor Model Platform engineers the tumor microenvironment in vitro at high throughput for drug efficacy and MOA studies. We are now applying ...
Cypre’s 3D Tumor Models combine the tumor, stromal and immune compartments in a high throughput format to screen targeted drugs and immunotherapy. In 2021, we partnered with Charles River to offer our 3D Tumor Models for drug ...
based inPlanegg, GERMANY
TQ Therapeutics GmbH is pioneering a novel approach to cell and gene therapy with its TQx platform, which transforms the production of cellular therapies into a rapid, automated process that occurs at the patient's side. This method leverages ...
based inNewcastle Upon Tyne, UNITED KINGDOM
Our mission at Alcyomics is to provide novel solutions for the assessment of safety and efficacy of pharmaceuticals, cosmetics and chemicals. As a service provider Alcyomics aspires to take the lead in providing unique screening services enabling ...
Development of complex and functional high-throughput in-vitro 3D tissue models for replicating disease states and high-throughput molecule ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
based inNew York, NEW YORK (USA)
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies ...
TARA-002 is an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). TARA-002 was developed from the same master cell bank of genetically distinct group A ...
based inVictoria, BRITISH COLUMBIA (CANADA)
Sepset Biosciences is a diagnostic company in advanced development of a blood test (Sepset-ER) for hospitals to identify patients in the emergency room (ER) who will acquire severe sepsis and have high risk for organ failure. Sepset’s test will ...
Sepset is developing a blood test for hospitals to identify septic patients in the emergency room (ER) and predict those who will have high risk for organ ...
based inNew York, NEW YORK (USA)
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted ...
based inCambridge, MASSACHUSETTS (USA)
At BlueRock, our mission is to create authentic cellular medicines to reverse devastating diseases, with the vision of improving the human condition. Until recently, scientists believed that mature adult cells were permanently locked into their ...
With our cell+gene platform, BlueRock is aiming to redefine the very way we treat disease, moving from addressing mere symptoms to restoring health lost to cell damage or degeneration. Instead of prescribing a pill ...
based in, CALIFORNIA (USA)
AIVITA Biomedical is a biotechnology company developing personalized vaccines that target COVID-19 and the seed of all cancers using our autologous cell platform. We leverage our unique expertise in stem cell growth and directed, high-purity ...
AIVITA’s immunotherapy technology creates personalized vaccines for cancer patients that target and eliminate tumor-initiating cells which are the seed of the disease. Used alone or in parallel with other treatments, AIVITA’s cancer ...
based inHuntsville, ALABAMA (USA)
SynVivo is a cell-based microfluidic organ-on-chip platform that provides a biologically realistic microenvironment for the real-time study of cellular behavior, drug delivery, and drug discovery. This proprietary technology links the high-tech ...
based inCambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Once ADCs release their cytotoxic payload into targeted cells, the drug is often able to cross cell membranes, entering and potentially killing neighboring cells whether those cells are cancerous or not. This effect is called bystander-killing, ...
